SPR 719
Alternative Names: SPR-719; VXC-486Latest Information Update: 18 Oct 2024
At a glance
- Originator Vertex Pharmaceuticals
- Developer Spero Therapeutics
- Class Antibacterials; Antituberculars
- Mechanism of Action DNA gyrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Nontuberculous mycobacterium infections
- No development reported Tuberculosis
Most Recent Events
- 16 Oct 2024 Antimicrobial data from a preclinical studies in Nontuberculous mycobacterium infections released by Spero Therapeutics
- 23 Feb 2024 Spero Therapeutics completes a phase I trial in Nontuberculous mycobacterium infections (In volunteers) in USA (PO) (NCT05955586)
- 01 Aug 2023 Phase-I clinical trials in Nontuberculous mycobacterium infections (In volunteers) in USA (PO) (NCT05955586)